Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...

Full description

Bibliographic Details
Main Authors: Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Akerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson, Rosaura Casas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22174945/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22174945/?tool=EBI

Similar Items